W.O. Böcher

LB01 SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR TREATMENT OF ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: FINAL RESULTS OF THE THE GERMAN HEPNET ACUTE HCV IV STUDY

Katja Deterding, Christoph D. Spinner, E. Schott, Tania M. Welzel et autres

Introduction Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa monotherapy is highly effective but is associated with frequent unfavorable side effects. There is no fully published study yet exploring the safety, efficacy and required treatment duration of interferon-free …

us, de, ch, it, nl, Égypte (code pays fourni par la source)

1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY

Stefan Zeuzem, Vincent Soriano, Tarik Asselah, J.-P. Bronowicki et autres

de, es, fr, au, nz, us, se (code pays fourni par la source)

1212 PHARMACOKINETIC MODELLING OF THE RELATIONSHIP BETWEEN SUSTAINED VIROLOGICAL RESPONSE AND PLASMA CONCENTRATIONS OF FALDAPREVIR OR BI-207127 IN HCV GT1-INFECTED PATIENTS IN SOUND-C2

S.C. Olson, Kyle Baron, Matthew Riggs, W.O. Böcher et autres

1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2

Tarik Asselah, S Zeuzem, Vincent Soriano, J.-P. Bronowicki et autres

fr, de, es, ch, au, nz, us, se (code pays fourni par la source)

101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2

Stefan Zeuzem, Vincent Soriano, Tarik Asselah, J.‐P. Bronowicki et autres

1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS

George Kukolj, Richard C. Bethell, Mariano Cartier, Alexandra Côté-Martin et autres

de (code pays fourni par la source)

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

Mark Sulkowski, E. Ceasu, Tarik Asselah, Florin Alexandru Căruntu et autres

us, ru, de, ro, fr, at, ar, au (code pays fourni par la source)

1249 BI201335 PHARMACOKINETICS AND EARLY EFFECT ON VIRAL LOAD IN HCV GENOTYPE-1 PATIENTS

Joseph Schérer, John P. Sabo, Jerry O. Stern, Gerhard Steinmann et autres

fr, us, de (code pays fourni par la source)

1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV

S. Pol, Thomas Berg, Maurizio Bonacini, M. Schuchmann et autres

es, fr, de, us (code pays fourni par la source)

66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R

Mark Sulkowski, Marc Bourlière, J.‐P. Bronowicki, Adrian Streinu‐Cercel et autres

us, fr, Ouganda, ca, de (code pays fourni par la source)

Untersuchungen zur Frage der Beeinflussung der Fahrtauglichkeit durch tägliche Einnahme von 3×1 Dragée Vesalium

W.O. Böcher, W. Nieschke, D. Schmidt, Gerhard Schubert et autres

DIE AN INSGESAMT 18 VPN DURCHGEFUEHRTEN UNTERSUCHUNGENWERDEN IM EINZELNEN BESCHRIEBEN UND DEREN ERGEBNISSE MITGETEILT. ES WIRD FESTGESTELLT, DASS AUS DEN ERHOBENEN BEFUNDENKEINE KONKRETEN ANHALTSPUNKTE ZU ENTNEHMEN SIND, OB DIEEINNAHME VON VERSALIUM IN EINER DOSIERUNG VON TAEGLICH3 X 1 DRAGE EINEN NENNENSWERTEN ODER …

de (code pays fourni par la source)

Buchbesprechungen — Book Reviews — Livres Nouveaux

M. Aurousseau, H. Eyraud, A. Lindner, B Rudas et autres

H ofm ann: E x p e rim e n te lle G ru n d la g e n d e r m u ltifa k to rie lle n G enese d e r S ch iz o p h …